Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non-small cell lung cancer (LOGIK1902).
Harada T, Sasaki T, Ishii H, Takemoto S, Hisamatsu Y, Saito H, Yoneshima Y, Komiya K, Kashiwabara K, Naoki K, Ogawa T, Takeoka H, Saruwatari K, Ito K, Tsuchiya-Kawano Y, Mizuno K, Shimose T, Shioyama Y, Okamoto I. Harada T, et al. Among authors: naoki k. Thorac Cancer. 2024 Oct;15(29):2128-2135. doi: 10.1111/1759-7714.15444. Epub 2024 Sep 8. Thorac Cancer. 2024. PMID: 39245951 Free PMC article. Clinical Trial.
Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.
Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, Zhao X, Naoki K, Okamoto I, Nakagawa K, Yeap BY, Meyerson M, Wong KK, Richards WG, Sugarbaker DJ, Johnson BE, Jänne PA. Koivunen JP, et al. Among authors: naoki k. Br J Cancer. 2008 Jul 22;99(2):245-52. doi: 10.1038/sj.bjc.6604469. Epub 2008 Jul 1. Br J Cancer. 2008. PMID: 18594528 Free PMC article.
Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
Misumi Y, Okamoto H, Sasaki J, Masuda N, Ishii M, Shimokawa T, Hosomi Y, Okuma Y, Nagamata M, Ogura T, Kato T, Sata M, Otani S, Takakura A, Minato K, Miura Y, Yokoyama T, Takata S, Naoki K, Watanabe K. Misumi Y, et al. Among authors: naoki k. BMC Cancer. 2017 May 26;17(1):377. doi: 10.1186/s12885-017-3353-y. BMC Cancer. 2017. PMID: 28549414 Free PMC article. Clinical Trial.
Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status.
Igawa S, Shirasawa M, Ozawa T, Nishinarita N, Okuma Y, Ono T, Sugimoto A, Kurahayashi S, Sugita K, Sone H, Fukui T, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K. Igawa S, et al. Among authors: naoki k. Thorac Cancer. 2018 Aug;9(8):967-973. doi: 10.1111/1759-7714.12772. Epub 2018 Jun 5. Thorac Cancer. 2018. PMID: 29870153 Free PMC article.
Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study.
Sone H, Igawa S, Kasajima M, Ishihara M, Hiyoshi Y, Hosotani S, Ohe S, Ito H, Kaizuka N, Manaka H, Fukui T, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K. Sone H, et al. Among authors: naoki k. Thorac Cancer. 2018 Oct;9(10):1279-1284. doi: 10.1111/1759-7714.12833. Epub 2018 Aug 20. Thorac Cancer. 2018. PMID: 30126051 Free PMC article.
Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease.
Igawa S, Nishinarita N, Takakura A, Ozawa T, Harada S, Kusuhara S, Niwa H, Hosotani S, Sone H, Nakahara Y, Fukui T, Mitsufuji H, Yokoba M, Kubota M, Katagiri M, Sasaki J, Naoki K. Igawa S, et al. Among authors: naoki k. Cancer Manag Res. 2018 Dec 14;10:7013-7019. doi: 10.2147/CMAR.S189556. eCollection 2018. Cancer Manag Res. 2018. PMID: 30588105 Free PMC article.
Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study.
Ono T, Igawa S, Ozawa T, Kasajima M, Ishihara M, Hiyoshi Y, Kusuhara S, Nishinarita N, Fukui T, Kubota M, Sasaki J, Hisashi M, Katagiri M, Naoki K. Ono T, et al. Among authors: naoki k. Thorac Cancer. 2019 Apr;10(4):880-889. doi: 10.1111/1759-7714.13018. Epub 2019 Feb 28. Thorac Cancer. 2019. PMID: 30821083 Free PMC article.
Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study.
Igawa S, Ono T, Kasajima M, Ishihara M, Hiyoshi Y, Kusuhara S, Nishinarita N, Fukui T, Kubota M, Sasaki J, Hisashi M, Yokoba M, Katagiri M, Naoki K. Igawa S, et al. Among authors: naoki k. Cancer Manag Res. 2019 May 28;11:4883-4892. doi: 10.2147/CMAR.S207170. eCollection 2019. Cancer Manag Res. 2019. PMID: 31213907 Free PMC article.
Prognostic significance of IMMT expression in surgically-resected lung adenocarcinoma.
Hiyoshi Y, Sato Y, Ichinoe M, Nagashio R, Hagiuda D, Kobayashi M, Kusuhara S, Igawa S, Shiomi K, Goshima N, Murakumo Y, Saegusa M, Satoh Y, Masuda N, Naoki K. Hiyoshi Y, et al. Among authors: naoki k. Thorac Cancer. 2019 Nov;10(11):2142-2151. doi: 10.1111/1759-7714.13200. Epub 2019 Oct 3. Thorac Cancer. 2019. PMID: 31583841 Free PMC article.
176 results